Ambrx Biopharma Future Growth
Future criteria checks 2/6
Ambrx Biopharma's earnings are forecast to decline at 9.4% per annum while its annual revenue is expected to grow at 64.5% per year. EPS is expected to decline by 14.5% per annum.
Key information
-9.4%
Earnings growth rate
-14.5%
EPS growth rate
| Biotechs earnings growth | 21.3% |
| Revenue growth rate | 64.5% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 23 Feb 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4 | -171 | -108 | -108 | 7 |
| 12/31/2025 | 4 | -126 | -96 | -62 | 9 |
| 12/31/2024 | 2 | -101 | N/A | -86 | 9 |
| 12/31/2023 | 2 | -80 | N/A | -68 | 9 |
| 9/30/2023 | 4 | -67 | -59 | -58 | N/A |
| 6/30/2023 | 6 | -60 | -56 | -55 | N/A |
| 3/31/2023 | 6 | -71 | -56 | -56 | N/A |
| 12/31/2022 | 7 | -78 | -70 | -69 | N/A |
| 9/30/2022 | 6 | -87 | -72 | -70 | N/A |
| 6/30/2022 | 5 | -91 | -70 | -68 | N/A |
| 3/31/2022 | 7 | -76 | -65 | -62 | N/A |
| 12/31/2021 | 7 | -68 | -48 | -45 | N/A |
| 9/30/2021 | 10 | -54 | -45 | -42 | N/A |
| 6/30/2021 | 12 | -40 | -41 | -40 | N/A |
| 3/31/2021 | 13 | -28 | -31 | -30 | N/A |
| 12/31/2020 | 14 | -17 | -21 | -21 | N/A |
| 12/31/2019 | 10 | -20 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMAM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AMAM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AMAM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AMAM's revenue (64.5% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: AMAM's revenue (64.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AMAM's Return on Equity is forecast to be high in 3 years time